Background: Genetic variants in miRNA genes and abnormalities in the concentration of microRNAs (miRNAs) in tissues and biological fluids have recently been associated with a diagnosis of schizophrenia. Most of these studies used post-mortem brain tissue or whole blood as the source of RNA. However, examination of microRNAs in cerebrospinal fluid (CSF) might provide an in vivo biomarker, more accurately reflecting expression level changes in the brain. To date, there are no studies that have investigated miRNA expression in CSF in patients with schizophrenia using small RNA-seq. In the past, our group had the opportunity of investigating the correlation between miRNA profiles in CSF and blood measured using microarray technology. Therefore, to expand our findings and use current cutting-edge technology, we measured miRNA profiles in CSF and plasma using small RNA-seq in a sample of patients with schizophrenia-spectrum disorder (SSD) diagnosis and healthy volunteers. Methods: Twenty-two SSD patients and 17 healthy volunteers underwent a lumbar puncture and a blood draw. 15-25 cc of CSF and 5-10 cc of peripheral blood were obtained from each subject. CSF and peripheral blood samples were centrifuged. CSF and plasma samples were aliquoted into 1 mL cryovials, and stored at -80C degrees. Vesicular RNA was extracted from 1 mL of CSF and plasma samples following the protocol from the Qiagen exoRNA easy kit. The BioScientific NextFlex RNA sequencing kit was used for library construction. Sequencing was done on HiSeq2500. Samples that had at least 50,000 reads going to mature miRNA sequences were included in the analysis. Differential expression analyses were conducted in R using the DESeq2 package in Bioconductor. Results: In the overall sample cohort, most subjects were male (66.7%), not Hispanic (81.0%) and black (48.7%). Mean age was 36.8 years (SD=12.3), There were no differences in age, sex, ethnicity or race between the patient and healthy control groups. In the patient group, 16 (72.7%) had schizophrenia, 5 (22.7%) had schizoaffective disorder and 1 (4.5%) had psychosis not otherwise specified. Differential expression (DE) analyses were conducted for 144 miRNAs in CSF and 354 miRNAs in plasma. After adjusting for multiple comparisons, DE analysis between patients and controls in CSF showed statistically significant higher levels in patients of miR-769-5p, miR-99b-3p, miR-107, miR451a and miR-708-5. Similar analysis in plasma showed statistically significant higher levels in patients for miR-375, miR-204-5p, miR-942-5p, miR-6734-5p, miR-423-5p and miR-144-5p. Principal component analysis showed a clear separation between CSF and peripheral blood samples. Out of 443 miRNAs used to examine the relationship between CSF and plasma, 205 (46.3%) were detected in both plasma and CSF samples, 88 (19.9%) were detected only in CSF samples while 150 (33.9%) were detected only in plasma samples. Discussion: Five miRNAs were upregulated in CSF samples and six were upregulated in plasma samples of SSD patients compared to healthy volunteers. There was no overlap in the statistically significant upregulated miRNAs between CSF and plasma samples. Therefore, miRNA profiles in CSF and plasma have important quantitative and qualitative differences that may make them excellent, but different, candidate biofluids for biomarker discovery.
Background: Changes in glutamatergic system, specifically the ionotropic receptor N-methyl-D-aspartate (NMDAR), are involved in psychosis. NMDARs could be composed of two NR1 and two NR2 subunits. NR1 is one obligatory subunit and is the glycine binding site; and NR2 subunit contain the binding site for the neurotransmitter glutamate and have four different subtypes including NR2A-D. NR1 and NR2A-B are essential subunits of NMDAR, which are encoded by genes Grin1, Grin2A and Grin2B, and have been identified as candidate genes for psychiatric disorders. NMDARs dysfunction disrupts neural excitation and to contribute to the altered brain function underlying, especially in schizophrenia and other psychosis. The aims of this work were 1) to evaluate the expression of Grin1, Grin2A and 2B genes by qPCR of patients with first episode of schizophrenia compared with the siblings and controls; 2) to quantify the NR1 and NR2 subunits plasma concentrations by ELISA; 3) to evaluate the Grin1, Grin2A and 2B gene expression by qPCR in peripheral blood and animals brain tissue. Methods: Participants will be 30 patients diagnosed with schizophrenia or schizophreniform disorder, including the shorter illness without substance addiction; those participants with siblings who agreed to participate (n = 30) and 30 controls, matched to patients by sex, age and education. Male Wistar rats were kept isolated (n = 10) or grouped (n = 10) from weaning for 10 weeks. After this period the animals were exposed to the Open Field and soon afterwards they were sacrificed, hippocampus and prefrontal cortex (PFC) were dissected to RNA extraction. RT-PCR was performed using probes and TaqMan mastermix to evaluate the mRNA expression. One-way ANOVA with a Bonferroni correction was used for statistical analysis. Results: Humans: Regarding the glutamatergic system, none of the chosen genes were expressed in the studied sample. Animals: Isolated reared animals presented hyperlocomotion at the two first time bins (0-5 and 5-10 min) in periphery of the arena when compared to the grouped [0-5 min: p = 0.025; 5-10 min: p = 0.002], respectively. Decreased expression of Grin1 (31%), Grin2A (45%) and Grin2B (52%) were found in PFC of isolated animals when compared to grouped (p < 0.05), while no changes were found in the hippocampus. Discussion: Changes in the expression of essential isoforms (NR1 and NR2) that make up NMDAR in PFC suggest abnormalities of glutamatergic neurotransmission in the pathophysiology of schizophrenia, corroborating recent studies. In addition, this study reinforces the validity of the social isolation rearing model from weaning with a better understanding of the mechanisms of NMDAR hypofunction and the influence of the environment on gene expression in this disorder.
